A Sudy to Evaluate the Efficacy and Safety of TNM001 in High-risk Infants
- Conditions
- Respiratory Syncytial Virus Infections
- Interventions
- Biological: placebo
- First Posted Date
- 2024-11-29
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- Zhuhai Trinomab Pharmaceutical Co., Ltd.
- Target Recruit Count
- 201
- Registration Number
- NCT06710925
- Locations
- 🇨🇳
West China Second University Hospital, Sichuan University, Chengdu, Sichuan, China
🇨🇳Children's Hospital of Chongqing Medical University, Chongqing, Sichuan, China
A Randomized, Open-Label, Parallel-Design Pharmacokinetic and Pharmacodynamic Interaction Study of TNM002 and Adsorbed Tetanus Vaccine
- Conditions
- Tetanus
- Interventions
- First Posted Date
- 2024-09-23
- Last Posted Date
- 2024-09-23
- Lead Sponsor
- Zhuhai Trinomab Pharmaceutical Co., Ltd.
- Target Recruit Count
- 60
- Registration Number
- NCT06607380
- Locations
- 🇨🇳
PKUCare Luzhong Hospital, Zibo, Shandong, China
A Trial to Evaluate the Efficacy and Safety of TNM001 for the Prevention of Lower Respiratory Tract Infection Caused by Respiratory Syncytial Virus in Infants
- Conditions
- Respiratory Syncytial Virus Infections
- Interventions
- Biological: placeboBiological: TNM001
- First Posted Date
- 2023-10-16
- Last Posted Date
- 2023-10-16
- Lead Sponsor
- Zhuhai Trinomab Pharmaceutical Co., Ltd.
- Target Recruit Count
- 2250
- Registration Number
- NCT06083623
- Locations
- 🇨🇳
The Third Affiliated Hospital of Guangzhou Medical University, Guangdong, Guangdong, China
🇨🇳Peking University Third Hospital, Beijing, Beijing, China
🇨🇳Children's Hospital Capital Institute Pediatrics, Beijing, Beijing, China
A Trial to Evaluate the Safety, Pharmacokinetics and Pharmacodynamic Profile of TNM005 in Healthy Adult Subjectsy
- First Posted Date
- 2023-10-05
- Last Posted Date
- 2024-07-11
- Lead Sponsor
- Zhuhai Trinomab Pharmaceutical Co., Ltd.
- Target Recruit Count
- 48
- Registration Number
- NCT06068608
- Locations
- 🇺🇸
ICON, plc, Salt Lake City, Utah, United States
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TNM002 in Chinese Healthy Adults
- First Posted Date
- 2023-05-06
- Last Posted Date
- 2023-05-06
- Lead Sponsor
- Zhuhai Trinomab Pharmaceutical Co., Ltd.
- Target Recruit Count
- 28
- Registration Number
- NCT05842798
- Locations
- 🇨🇳
The Fifth Affiliated Hospital Sun Yat-sen University, Zhuhai, Guangdong, China
Study to Compare the Efficacy and Safety of Passive Immunization With TNM002 Injection and Human Tetanus Immunoglobulin as Prophylaxis Against Tetanus
- First Posted Date
- 2022-12-27
- Last Posted Date
- 2024-03-08
- Lead Sponsor
- Zhuhai Trinomab Pharmaceutical Co., Ltd.
- Target Recruit Count
- 675
- Registration Number
- NCT05664750
- Locations
- 🇨🇳
PKUCare Luzhong Hospital, Zibo, Shandong, China
🇨🇳The Second Xiangya Hospital of Central South University, Changsha, Hunan, China
🇨🇳Guangzhou First People's Hospital, Guangzhou, Guangdong, China
A Study of TNM001 in Chinese Healthy Preterm and Term Infants
- Conditions
- Respiratory Syncytial Virus Infections
- Interventions
- Biological: TNM001Biological: Placebo
- First Posted Date
- 2022-11-29
- Last Posted Date
- 2024-06-28
- Lead Sponsor
- Zhuhai Trinomab Pharmaceutical Co., Ltd.
- Target Recruit Count
- 31
- Registration Number
- NCT05630573
- Locations
- 🇨🇳
The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei, China
🇨🇳Hunan Provincial People's Hospital, Changsha, Hunan, China
🇨🇳The Third Xiangya Hospital of Central South University, Changsha, Hunan, China
Study to Compare the Anti-tetanus Neutralizing Antibody Titers and Safety of TNM002 Injection With Human Tetanus Immunoglobulin or Placebo in Adult Volunteers
- Conditions
- Tetanus
- Interventions
- Biological: TNM002 (low dose)Biological: TNM002 (high dose)Biological: HTIGBiological: TNM002 (medium dose)Biological: Placebo
- First Posted Date
- 2022-11-23
- Last Posted Date
- 2023-05-23
- Lead Sponsor
- Zhuhai Trinomab Pharmaceutical Co., Ltd.
- Target Recruit Count
- 240
- Registration Number
- NCT05625477
- Locations
- 🇨🇳
Wuxi People's Hospital, Wuxi, Jiangsu, China
🇨🇳The First Affiliated Hospital of Shantou University Medical College, Shantou, Guangdong, China
🇨🇳PKUCare Luzhong Hospital, Zibo, Shandong, China
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TNM002 in Healthy Adults
- Conditions
- Healthy Adult Subjects
- Interventions
- Biological: TNM002 Dosage 1 (10 μg/kg)Biological: TNM002 Dosage 4 (250 μg/kg)Biological: TNM002 Dosage 2 (35 μg/kg)Biological: TNM002 Dosage 3 (100 μg/kg)Biological: Placebo
- First Posted Date
- 2020-11-16
- Last Posted Date
- 2022-11-07
- Lead Sponsor
- Zhuhai Trinomab Pharmaceutical Co., Ltd.
- Target Recruit Count
- 32
- Registration Number
- NCT04629131
- Locations
- 🇦🇺
Scientia Clinical Research, Sydney, New South Wales, Australia